{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:08:57Z","timestamp":1787688537311,"version":"build-2784847793"},"reference-count":170,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Monash University, Melbourne"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide, with an estimated global prevalence of 38% in adults. MASLD confers a significant increase in morbidity and mortality due to its association with cardiovascular disease and progressive liver disease, including cirrhosis and hepatocellular carcinoma. Current treatment paradigms for MASLD are centred around lifestyle modification and weight loss, with a need for pharmacotherapeutic options. Given the strong relationship between MASLD and cardiovascular disease, there is an interest in evaluating the efficacy and safety of cardiovascular medications such as statins in liver disease. Statins are the most commonly prescribed lipid-lowering medication in the world, with an established role in reducing cardiovascular morbidity and mortality. Statins are currently under-prescribed in the MASLD patient population, yet there is growing interest in determining whether statins could be utilised to treat MASLD itself. This comprehensive review aims to explore the evidence regarding the use of statin therapy for conventional, lipid-lowering indications in patients with MASLD and its potential benefits for the treatment of MASLD and its complications.<\/jats:p>","DOI":"10.3390\/medsci14010084","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:28:11Z","timestamp":1770910091000},"page":"84","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"I.","family":"Commins","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne, VIC 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-9669","authenticated-orcid":false,"given":"D.","family":"Clayton-Chubb","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne, VIC 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia"},{"name":"Department of Gastroenterology, Eastern Health, Box Hill, VIC 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Janko","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia"},{"name":"Department of Gastroenterology, Eastern Health, Box Hill, VIC 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne, VIC 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-7273","authenticated-orcid":false,"given":"W.","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne, VIC 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-7997","authenticated-orcid":false,"given":"S. K.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne, VIC 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s12072-024-10706-1","article-title":"NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): A 20-year longitudinal follow-up study from regional Australia","volume":"18","author":"Vaz","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Askling","year":"2010","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1098\/rstb.2009.0137","article-title":"Human population growth and the demographic transition","volume":"364","author":"Bongaarts","year":"2009","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(09)61460-4","article-title":"Ageing populations: The challenges ahead","volume":"374","author":"Christensen","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/liv.15725","article-title":"Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage","volume":"44","author":"Kemp","year":"2024","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes. Facts, 17, 374\u2013444.","DOI":"10.1159\/000539371"},{"key":"ref_11","first-page":"167","article-title":"Pathogenesis and Prevention of Hepatic Steatosis","volume":"11","author":"Nassir","year":"2015","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: From plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity: Mechanistic insights and clinical implications","volume":"124","author":"Ward","year":"2019","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: Mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: A review of clinical and therapeutical implications","volume":"40","author":"Buhaescu","year":"2007","journal-title":"Clin. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"ref_19","unstructured":"Gu, Q. (2014). Prescription Cholesterol-Lowering Medication Use in Adults Aged 40 and Over: United States, 2003\u20132012, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"d4350","DOI":"10.1136\/bmj.d4350","article-title":"Statin prescriptions in UK now total a million each week","volume":"343","author":"Trusler","year":"2011","journal-title":"BMJ"},{"key":"ref_21","unstructured":"Bansal, A.B., and Cassagnol, M. (2023). HMG-CoA reductase inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Climent, E., Benaiges, D., and Pedro-Botet, J. (2021). Hydrophilic or Lipophilic Statins?. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.687585"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance\u2014An attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists\u2019(CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","article-title":"Under-prescription of statins in patients with non-alcoholic fatty liver disease","volume":"27","author":"Baratta","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial","volume":"102","author":"Bril","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.aohep.2022.100738","article-title":"Safety and efficacy of dyslipidemia treatment in NAFLD patients: A meta-analysis of randomized controlled trials","volume":"27","author":"Abdallah","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/apt.16646","article-title":"Trends in statin utilisation in US adults with non-alcoholic fatty liver disease","volume":"54","author":"Henson","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Vessby","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12072-024-10748-5","article-title":"MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study","volume":"19","author":"Vaz","year":"2025","journal-title":"Hepatol. Int."},{"key":"ref_36","first-page":"e10446","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan","year":"2020","journal-title":"Cureus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.dld.2014.04.002","article-title":"Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals","volume":"46","author":"Koehler","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study","volume":"116","author":"Lee","year":"2021","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1570161115666170630122833","article-title":"Effect of low (5 mg) vs. high (20\u201340 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension","volume":"16","author":"Mitsiou","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cho, Y., Rhee, H., Kim, Y.E., Lee, M., Lee, B.W., Kang, E.S., Cha, B.S., Choi, J.Y., and Lee, Y.H. (2022). Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med., 20.","DOI":"10.1186\/s12916-022-02288-2"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103126","DOI":"10.1016\/j.dsx.2024.103126","article-title":"Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial","volume":"18","author":"Wang","year":"2024","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1570161118666201015152921","article-title":"Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?","volume":"19","author":"Sfikas","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_44","first-page":"CD008623","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"154752","DOI":"10.1016\/j.metabol.2021.154752","article-title":"Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes","volume":"121","author":"Ciardullo","year":"2021","journal-title":"Metabolism"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1210\/jc.2018-01446","article-title":"Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial","volume":"103","author":"Braun","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2007.02.009","article-title":"Epidemiology and Natural History of NAFLD and NASH","volume":"11","author":"Ong","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101816","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clinthera.2025.05.006","article-title":"New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial","volume":"47","author":"Zakaria","year":"2025","journal-title":"Clin. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5694\/mja2.52104","article-title":"Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: A retrospective cohort study","volume":"219","author":"Skoien","year":"2023","journal-title":"Med. J. Aust."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"ref_58","first-page":"2","article-title":"Diabetes mellitus, insulin, sulfonylurea and advanced fibrosis in non-alcoholic fatty liver disease","volume":"5","author":"Goh","year":"2014","journal-title":"J. Diabetes Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.arcmed.2013.12.003","article-title":"Statin Use Is Not Associated with Presence of and Severity of Nonalcoholic Fatty Liver Disease","volume":"45","author":"Oni","year":"2014","journal-title":"Arch. Med. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_61","first-page":"92","article-title":"Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with \u03b1-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients","volume":"11","author":"Malaguarnera","year":"2011","journal-title":"Hepat. Mon."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1570161115666170621082910","article-title":"Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk","volume":"16","author":"Athyros","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5114\/aoms.2011.25554","article-title":"Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study","volume":"7","author":"Athyros","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5694\/mja2.70008","article-title":"Assessment of metabolic dysfunction-associated fatty liver disease in primary care: A consensus statement summary","volume":"223","author":"Adams","year":"2025","journal-title":"Med. J. Aust."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","article-title":"Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC","volume":"78","author":"Sharpton","year":"2023","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicity\/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sung, S., Al-Karaghouli, M., Kalainy, S., Cabrera Garcia, L., and Abraldes, J.G. (2021). A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01704-w"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","article-title":"Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment","volume":"58","author":"Simonson","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2125.2004.02251.x","article-title":"Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis","volume":"59","author":"Hui","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"375S","DOI":"10.1093\/ajh\/6.11.375S","article-title":"Pharmacokinetics of fluvastatin and specific drug interactions","volume":"6","author":"Smith","year":"1993","journal-title":"Am. J. Hypertens."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/sj.bjp.0704173","article-title":"Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins)","volume":"133","author":"Eberlein","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular pathobiology in chronic liver disease and cirrhosis\u2013Current status and future directions","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.LAB.0000017365.18894.D3","article-title":"Effects and regulation of connective tissue growth factor on hepatic stellate cells","volume":"82","author":"Paradis","year":"2002","journal-title":"Lab. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bpg.2011.02.011","article-title":"Anti-fibrogenic strategies and the regression of fibrosis","volume":"25","author":"Kisseleva","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: A systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamainternmed.2025.0115","article-title":"Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease","volume":"185","author":"Choi","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated cirrhosis: Natural history and prognostic factors","volume":"7","author":"Quintero","year":"1987","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e70326","DOI":"10.1111\/liv.70326","article-title":"Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta-Analysis","volume":"45","author":"Abdulrazzak","year":"2025","journal-title":"Liver Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial","volume":"47","author":"Soldan","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: A proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/HEP.0000000000001148","article-title":"Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to \u03b2-blockers: A double-blind, placebo-controlled, randomized trial","volume":"82","author":"Brujats","year":"2025","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: A randomized controlled trial","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e0332","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial","volume":"7","author":"Kronborg","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and rifaximin in decompensated cirrhosis: A randomized clinical trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C\u2013related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus\u2013and hepatitis C virus\u2013related cirrhosis: A population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: A retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin Use Is Associated with Improved Outcomes of Patients with Primary Sclerosing Cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/apt.12430","article-title":"Statin use and infections in Veterans with cirrhosis","volume":"38","author":"Pakyz","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","article-title":"Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort","volume":"76","author":"Mahmud","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","article-title":"Cholesteryl ester accumulation induced by PTEN loss and PI3K\/AKT activation underlies human prostate cancer aggressiveness","volume":"19","author":"Yue","year":"2014","journal-title":"Cell Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1096\/fj.03-0261fje","article-title":"Lovastatin inhibits Rho-regulated expression of E-selectin by TNF-\u03b1 and attenuates tumor cell adhesion","volume":"18","author":"Dippold","year":"2004","journal-title":"FASEB J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/bjc.2012.138","article-title":"The differential effects of statins on the metastatic behaviour of prostate cancer","volume":"106","author":"Brown","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/hc0602.103393","article-title":"Statins have biphasic effects on angiogenesis","volume":"105","author":"Weis","year":"2002","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ijc.30506","article-title":"Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study","volume":"140","author":"Kim","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/MCG.0000000000001260","article-title":"Statin use is protective against hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A case-control study","volume":"54","author":"German","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins Are Associated with a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients with Diabetes","volume":"136","author":"Johnson","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5582\/bst.2017.01191","article-title":"Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection","volume":"11","author":"Kawaguchi","year":"2017","journal-title":"Biosci. Trends"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41598-018-38110-4","article-title":"Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients","volume":"9","author":"Cho","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/lt.25067","article-title":"Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation","volume":"24","author":"Patel","year":"2018","journal-title":"Liver Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1053\/j.gastro.2016.06.055","article-title":"Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis","volume":"151","author":"Weersink","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jgh.12657","article-title":"Severe hepatic injury associated with different statins in patients with chronic liver disease: A nationwide population-based cohort study","volume":"30","author":"Chang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Gu, Y., Yang, X., Liang, H., and Li, D. (2019). Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: A systematic review and meta-analysis. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-1147-1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7326\/M18-2753","article-title":"Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: Results from a nationwide Swedish population","volume":"171","author":"Simon","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Facciorusso, A., Abd El Aziz, M.A., Singh, S., Pusceddu, S., Milione, M., Giacomelli, L., and Sacco, R. (2020). Statin use decreases the incidence of hepatocellular carcinoma: An updated meta-analysis. Cancers, 12.","DOI":"10.3390\/cancers12040874"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Li, X., Sheng, L., Liu, L., Hu, Y., Chen, Y., and Lou, L. (2020). Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: A meta-analysis. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01222-1"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2016.07.009","article-title":"Statin intolerance: A literature review and management strategies","volume":"59","author":"Saxon","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOL.0000000000000236","article-title":"Statin intolerance","volume":"26","author":"Laufs","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/2047487315602861","article-title":"Statin tolerability: In defence of placebo-controlled trials","volume":"23","author":"Tobert","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacl.2017.01.006","article-title":"Statin-associated muscle symptoms\u2014Managing the highly intolerant","volume":"11","author":"Backes","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms","volume":"111","author":"Niemi","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","article-title":"Lipid-lowering agents that cause drug-induced hepatotoxicity","volume":"11","author":"Bhardwaj","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Jacobsen","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jacl.2017.03.003","article-title":"Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials","volume":"11","author":"Bytyci","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: A systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/liv.13308","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","volume":"37","year":"2017","journal-title":"Liver Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","article-title":"Autoimmune hepatitis triggered by statins","volume":"40","author":"Alla","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity: A meta-analysis","volume":"24","author":"Spinler","year":"2004","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e33981","DOI":"10.1097\/MD.0000000000033981","article-title":"Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacl.2012.01.009","article-title":"Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)","volume":"6","author":"Han","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"ref_137","first-page":"228","article-title":"Statin treatment and increased diabetes risk. Possible mechanisms","volume":"31","author":"Climent","year":"2019","journal-title":"Cl\u00ednica Investig. Arterioscler. (Engl. Ed.)"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/00325481.2017.1292107","article-title":"New onset diabetes mellitus induced by statins: Current evidence","volume":"129","author":"Chrysant","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"g3244","DOI":"10.1136\/bmj.g3244","article-title":"Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases","volume":"348","author":"Dormuth","year":"2014","journal-title":"BMJ Br. Med. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjcard.2005.11.014","article-title":"Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)\u2014Can C-reactive protein be used to target statin therapy in primary prevention?","volume":"97","author":"Mora","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/j.1552-4604.1996.tb04242.x","article-title":"Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects","volume":"36","author":"Posvar","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","article-title":"The role of statins in both cognitive impairment and protection against dementia: A tale of two mechanisms","volume":"7","author":"Schultz","year":"2018","journal-title":"Transl. Neurodegener."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/HCO.0000000000000082","article-title":"Statins in the elderly: An answered question?","volume":"29","author":"Zoungas","year":"2014","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.amjcard.2005.12.007","article-title":"Statin Safety and Drug Interactions: Clinical Implications","volume":"97","author":"Bottorff","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A., Fu, R., and Ferencik, M. (2022). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the US Preventive Services Task Force, Agency for Healthcare Research and Quality.","DOI":"10.1001\/jama.2022.12138"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","article-title":"Rosuvastatin safety: Lessons from the FDA review and post-approval surveillance","volume":"3","author":"Davidson","year":"2004","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2011.09.067","article-title":"Meta-Analysis of Statin Effects in Women Versus Men","volume":"59","author":"Kostis","year":"2012","journal-title":"JACC"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_155","first-page":"211","article-title":"Are statin side effects dependent on sex? A narrative review","volume":"24","author":"Moszak","year":"2025","journal-title":"Prz. Menopauzalny"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e005562","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex Differences in the Use of Statins in Community Practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e004343","DOI":"10.1136\/bmjdrc-2024-004343","article-title":"Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration","volume":"12","author":"Kao","year":"2024","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.cgh.2022.03.020","article-title":"Statins Are Underused in Women with NAFLD After Cardiovascular Events Compared with Matched Control Subjects","volume":"21","author":"Shang","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Zhang, H., Plutzky, J., Shubina, M., and Turchin, A. (2016). Drivers of the sex disparity in statin therapy in patients with coronary artery disease: A cohort study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155228"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: Insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2014.10924","article-title":"Evaluation and treatment of older patients with hypercholesterolemia: A clinical review","volume":"312","author":"Strandberg","year":"2014","journal-title":"JAMA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.39241.630741.BE1","article-title":"Preventive health care in elderly people needs rethinking","volume":"335","author":"Mangin","year":"2007","journal-title":"BMJ"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e069915","DOI":"10.1136\/bmjopen-2022-069915","article-title":"Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: Protocol for a randomised controlled trial in primary care (STAREE trial)","volume":"13","author":"Zoungas","year":"2023","journal-title":"BMJ Open"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Zhou, L., Wu, B., Bian, Y., Lu, Y., Zou, Y., Lin, S., Li, Q., and Liu, C. (2025). Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0327500"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0029-1240010","article-title":"Drug-induced liver injury associated with statins","volume":"29","author":"Russo","year":"2009","journal-title":"Semin. Liver Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary Prevention of Cardiovascular Events with Long-Term Pravastatin in Patients with Diabetes or Impaired Fasting Glucose: Results from the LIPID trial","volume":"26","author":"Keech","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3949\/ccjm.90a.22069","article-title":"Statins may increase diabetes, but benefit still outweighs risk","volume":"90","author":"Hoogwerf","year":"2023","journal-title":"Cleve Clin. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Kearney, P.M., Blackwell, L., Collins, R., Keech, A., Simes, J., Peto, R., Armitage, J., and Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet, 371, 117\u2013125.","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"ref_170","first-page":"S179","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142024","volume":"47","author":"Committee","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/84\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:57:28Z","timestamp":1770911848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":170,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medsci14010084"],"URL":"https:\/\/doi.org\/10.3390\/medsci14010084","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}